Zhejiang Orient Gene Biotech Co Ltd (688298) - Total Liabilities
Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has total liabilities worth CN¥1.01 Billion CNY (≈ $148.51 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688298 cash generation efficiency to assess how effectively this company generates cash.
Zhejiang Orient Gene Biotech Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Zhejiang Orient Gene Biotech Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Zhejiang Orient Gene Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen Aoto Electronics Co Ltd
SHE:002587
|
China | CN¥616.77 Million |
|
Dook Media Group Limited
SHE:301025
|
China | CN¥93.88 Million |
|
MAS Financial Services Limited
NSE:MASFIN
|
India | Rs102.87 Billion |
|
Transcat Inc
NASDAQ:TRNS
|
USA | $176.12 Million |
|
Daily Journal Corp
NASDAQ:DJCO
|
USA | $146.36 Million |
|
Western Copper and Gold Corp
TO:WRN
|
Canada | CA$5.48 Million |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
China | CN¥663.71 Million |
|
Advanced Nano Products Co. Ltd
KQ:121600
|
Korea | ₩203.23 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Zhejiang Orient Gene Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688298 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Orient Gene Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.30 Billion ≈ $190.69 Million |
-9.89% |
| 2023-12-31 | CN¥1.45 Billion ≈ $211.63 Million |
-39.25% |
| 2022-12-31 | CN¥2.38 Billion ≈ $348.38 Million |
+14.01% |
| 2021-12-31 | CN¥2.09 Billion ≈ $305.57 Million |
+86.14% |
| 2020-12-31 | CN¥1.12 Billion ≈ $164.16 Million |
+944.66% |
| 2019-12-31 | CN¥107.38 Million ≈ $15.71 Million |
-17.15% |
| 2018-12-31 | CN¥129.62 Million ≈ $18.97 Million |
+6.94% |
| 2017-12-31 | CN¥121.20 Million ≈ $17.74 Million |
-14.82% |
| 2016-12-31 | CN¥142.28 Million ≈ $20.82 Million |
-- |
About Zhejiang Orient Gene Biotech Co Ltd
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunologic… Read more